The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II study of everolimus, letrozole, and metformin in women with advanced/recurrent endometrial cancer.
 
Pamela T. Soliman
Research Funding - Novartis (Inst)
 
Shannon Neville Westin
Consulting or Advisory Role - Amgen (I); AstraZeneca; Medivation; Novartis (I); Ovation Sciences; Roche; Spectrum Pharmaceuticals (I)
Research Funding - AstraZeneca; Biomarin; Celgene (I); Critical Outcome Technologies; GlaxoSmithKline; Janssen (I); Karyopharm Therapeutics (I); Merck; Millennium (I); Novartis; ProNAi (I); Spectrum Pharmaceuticals (I)
 
David A Iglesias
No Relationships to Disclose
 
Mark F. Munsell
No Relationships to Disclose
 
Brian M. Slomovitz
Consulting or Advisory Role - Janssen
 
Karen H. Lu
No Relationships to Disclose
 
Robert L. Coleman
Honoraria - NCCN
Consulting or Advisory Role - Clovis Oncology; DOD-CDRMP; Esperance Pharmaceuticals; Genentech/Roche; NCCN
Research Funding - Amgen; Array BioPharma; AstraZeneca/MedImmune; Clovis Oncology; Esperance Pharmaceuticals; Johnson & Johnson; Merrimack; OncoMed
Travel, Accommodations, Expenses - Amgen; Array BioPharma; AstraZeneca/MedImmune; Bayer; Clovis Oncology; Gradalis; Merck; Merrimack; Millennium